NASD · Healthcare · Biotechnology · USA
Xencor Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies for treating cancer and autoimmune diseases. The company uses protein engineering to design XmAb candidates with novel mechanisms of action, advancing them through clinical studies. Its portfolio includes bispecific antibodies targeting oncology and autoimmune indications, with marketed medicines developed using its XmAb technologies.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Xencor Inc stock.
Overvalued: intrinsic value $4.80 per share, market price $34.50, margin of safety -619.3% (as of 2026-11-17).
Its liquidation floor, current assets minus every liability, values the shares at $4.80; the price of $34.50 is 619% above that value.
17 more funds hold it; the full list is part of the paid plan.
98 more in this industry show a wider margin of safety.
XNCR is overvalued (as of the 2026-11-17 close). Its liquidation floor, current assets minus every liability, values the shares at $4.80; the price of $34.50 is 619% above that value.
$4.80 per share (as of the 2026-11-17 close), against a market price of $34.50. That is a margin of safety of -619.3%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.